Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide and Insulin Fixed-Dose Ratio in T1DM
NCT02500979Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in type 1 diabetes mellitus (T1D) comparing Pramlintide Sequence with Placebo Sequence (2 arms). Primary endpoint: 24-hour Tissue Mean Weighted Glucose (MWG). Started Aug 2015; status: completed.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02500979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500979.